INTCO MEDICAL(SZ:300677) Zheng Quan Shi Bao Wang·2025-10-20 13:49Core Viewpoint - Company Inke Medical announced an investment of $70 million in Warburg Pincus Global Growth 15, L.P., which is part of a larger fundraising effort targeting $17 billion across various high-potential sectors, including healthcare and technology [1][2]. Group 1: Investment Details - The investment will be made by Inke Medical's wholly-owned subsidiary, Inke Medical International (Hong Kong) Limited, and will be paid in cash over six years [1]. - The investment constitutes a related party transaction as a subsidiary of Inke Medical's affiliate, Inke Recycling Resources Co., Ltd., is also participating in the fund as a limited partner [2]. Group 2: Fund Management and Fee Structure - Warburg Pincus LLC will manage the fund, with the general partner holding exclusive management and control rights [2]. - The fund will charge a management fee of 1.3% for the first eight years, decreasing to 1.25% in years nine and ten, and 1% thereafter [2]. - Profit distribution will occur only after certain conditions are met, with 80% of remaining net profits allocated to limited partners and 20% to the general partner [2]. Group 3: Strategic Alignment and Market Position - Inke Medical views the partnership with Warburg Pincus as a way to enhance capital efficiency and expected returns, aligning with its long-term business strategy in the global healthcare sector [3]. - Warburg Pincus has a strong track record, managing over $86 billion in assets and investing in over a thousand companies globally, which positions it as a leading investment institution [3]. - The investment direction of the fund aligns closely with Inke Medical's core business, potentially leading to business synergies and resource complementarity [3].